Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.

Raymond Schinazi Biography and Net Worth

Major Shareholder of Cocrystal Pharma

Mr. Raymond Schinazi is the Major Shareholder of Cocrystal Pharma.

What is Raymond F. Schinazi's net worth?: The estimated net worth of Raymond F. Schinazi is at least $11.67 million as of May 4th, 2021. Mr. Schinazi owns 7,674,960 shares of Cocrystal Pharma stock worth more than $11,665,939 as of April 23rd. This net worth estimate does not reflect any other investments that Mr. Schinazi may own. Learn More about Raymond F. Schinazi's net worth.
How do I contact Raymond F. Schinazi?: The corporate mailing address for Mr. Schinazi and other Cocrystal Pharma executives is 19805 N. CREEK PARKWAY, BOTHELL WA, 98011. Cocrystal Pharma can also be reached via phone at (305) 425-1780 and via email at [email protected]. Learn More on Raymond F. Schinazi's contact information.
Has Raymond F. Schinazi been buying or selling shares of Cocrystal Pharma?: Raymond F. Schinazi has not been actively trading shares of Cocrystal Pharma during the last quarter. Most recently, Raymond F. Schinazi sold 575,000 shares of the business's stock in a transaction on Tuesday, May 4th. The shares were sold at an average price of $2.95, for a transaction totalling $1,696,250.00. Following the completion of the sale, the insider now directly owns 7,674,960 shares of the company's stock, valued at $22,641,132. Learn More on Raymond F. Schinazi's trading history.
Who are Cocrystal Pharma's active insiders?: Cocrystal Pharma's insider roster includes Richard Pfenniger, Jr. (Director), and Raymond Schinazi (Major Shareholder). Learn More on Cocrystal Pharma's active insiders.

Raymond F. Schinazi Insider Trading History at Cocrystal Pharma

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/4/2021	Sell	575,000	$2.95	$1,696,250.00	7,674,960
10/25/2019	Buy	16,935	$1.11	$18,797.85
9/1/2016	Buy	4,878,050	$0.41	$2,000,000.50	275,520,853
4/21/2015	Buy	3,464,855	$0.92	$3,187,666.60

Raymond F. Schinazi Buying and Selling Activity at Cocrystal Pharma

Cocrystal Pharma Company Overview

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.

Today's Range

Now: $1.52

$1.49

$1.57

50 Day Range

MA: $1.49

$1.40

$1.60

2 Week Range

Now: $1.52

$1.33

$3.29

Volume

9,707 shs

Average Volume

13,622 shs

Market Capitalization

$15.46 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.34

Claim Your Complimentary Bitcoin Reward

From Crypto Swap Profits | Ad

Secure Your Spot Now